Novo SVP on new acquisition: "Leading and unique in the field"
Novo Nordisk has searched far and wide for a company to help the Danish drug group one step closer to the development of "intelligent" insulin. British Ziylo was chosen for the job and according to Senior Vice President of Global Drug Discovery, Marcus Schindler, the company is leading in the field.
Recently, Novo Nordisk announced that the drug group has acquired Ziylo, a University of Bristol spin-out company, in a deal with a potential vaue of more than DKK 5 billion (USD 800 million).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
